# ClinicalIntelPulse FDA/EMA Drug Approval Outlook

> ClinicalIntelPulse FDA/EMA Drug Approval Outlook is a paid API for AI agents from clinicalintelpulse.theaslangroupllc.com, paid per call via x402, $0.25/call, status unknown (last checked 2026-09-14).

Returns FDA/EMA approval probability scores and PDUFA calendar for Phase 3 drugs in a given disease area, including mechanism of action, trial results, and historical phase-3 success rates.

## Facts

- Endpoint: GET https://clinicalintelpulse.theaslangroupllc.com/api/clinical/approval-outlook
- Price: $0.25/call
- Payment: x402
- Status: unknown
- Last checked: 2026-09-14
- Activations on Zero: 0
- Tags: x402
- Canonical page: https://www.zero.xyz/c/clinicalintelpulse-fda-ema-drug-approval-outlook-b10b73c2
- Structured record (JSON): https://api.zero.xyz/v1/capabilities/cap_BicwJJJ1iUmcAl5wuuaKw

Status and success rate cover calls made through Zero and Zero's own probes. Third-party monitors may report differently.

## How to call it through Zero

Zero handles the 402 payment challenge and records the run. With the Zero CLI installed (`npm i -g @zeroxyz/cli`):

```sh
zero fetch --capability clinicalintelpulse-fda-ema-drug-approval-outlook-b10b73c2
```

Example prompt: What are the Phase 3 drugs most likely to win FDA or EMA approval in the next 12-24 months for non-alcoholic steatohepatitis (NASH) — I want approval probability scores, PDUFA dates, mechanism of action, and historical phase-3 success rates for the disease area.

## When to prefer this

Use this endpoint when you need forward-looking regulatory approval probability for late-stage (Phase 3) drugs in a specific disease area, particularly for biotech investment due diligence, payer launch planning, or competitive intelligence. Prefer this over a general trial landscape endpoint when the primary question is 'which drugs are most likely to be approved and when?' rather than 'what trials exist?'

## Known failure modes

- Unknown or misspelled disease area returns empty results or a 404
- Disease area with no active Phase 3 trials returns an empty pipeline list
- Overly broad therapeutic areas (e.g. 'cancer') may return truncated or paginated results
- Stale PDUFA calendar data if FDA/EMA has not yet published dates for recent filings
- Rate limiting or payment failure returns 402 Payment Required

## How this service works

FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results, approval-probability scores and historical phase-3 success rates. Worldwide. For biotech-investing and payer agents.

## Output

A ranked list of Phase 3 drugs in the queried disease area, each with an approval probability score, expected PDUFA date, mechanism of action, summary of pivotal trial results, and the historical phase-3 success rate for that indication — sourced globally covering both FDA and EMA pipelines.

## Request schema (JSON Schema)

```json
{
 "type": "object",
 "$schema": "https://json-schema.org/draft/2020-12/schema",
 "required": [
  "input"
 ],
 "properties": {
  "input": {
   "type": "object",
   "required": [
    "type",
    "method"
   ],
   "properties": {
    "type": {
     "type": "string",
     "const": "http"
    },
    "method": {
     "enum": [
      "GET",
      "HEAD",
      "DELETE"
     ],
     "type": "string"
    },
    "queryParams": {
     "type": "object",
     "properties": {
      "lang": {
       "type": "string"
      },
      "agency": {
       "type": "string"
      },
      "horizon": {
       "type": "string"
      },
      "condition": {
       "type": "string"
      }
     }
    }
   },
   "additionalProperties": false
  },
  "output": {
   "type": "object",
   "required": [
    "type"
   ],
   "properties": {
    "type": {
     "type": "string"
    },
    "errors": {
     "type": "object",
     "description": "Documented error responses, keyed by HTTP status code",
     "additionalProperties": {
      "type": "object",
      "required": [
       "description"
      ],
      "properties": {
       "example": {
        "type": "object"
       },
       "description": {
        "type": "string"
       }
      }
     }
    },
    "example": {
     "type": "object"
    }
   }
  }
 }
}
```

## Response schema (JSON Schema)

```json
{
 "type": "json",
 "example": {
  "query_summary": {
   "horizon": "18m",
   "agencies": [
    "FDA",
    "EMA"
   ],
   "condition": "Alzheimer Disease"
  },
  "market_context": "Alzheimer's is the highest-value CNS approval category. Any successful amyloid or tau therapy represents $5-15B peak sales potential.",
  "pdufa_calendar": [
   {
    "drug": "Donanemab",
    "sponsor": "Eli Lilly",
    "indication": "Early symptomatic AD",
    "pdufa_date": "2025-Q2",
    "priority_review": true
   }
  ],
  "approval_candidates": [
   {
    "drug": "Lecanemab (Leqembi)",
    "nctId": "NCT03887455",
    "sponsor": "Eisai / Biogen",
    "key_risk": "ARIA (amyloid-related imaging abnormalities) safety profile limiting real-world use",
    "mechanism": "Anti-amyloid monoclonal antibody (protofibrils)",
    "ema_status": "CHMP assessment ongoing 2025",
    "fda_status": "Full approval received 2023; expanded label applications pending",
    "trial_result": "Positive — 27% slowing of clinical decline vs placebo (p<0.001)",
    "approval_probability": 85
   }
  ],
  "approval_rate_context": {
   "rare_disease_premium": "Breakthrough therapy designation adds ~15% probability uplift",
   "us_approval_rate_phase3_pct": 58,
   "disease_area_historical_phase3_success_pct": 55
  }
 }
}
```

## More

- Live health (JSON, refreshed every minute): https://www.zero.xyz/c/clinicalintelpulse-fda-ema-drug-approval-outlook-b10b73c2/health.json
- [Zero catalog index](https://www.zero.xyz/llms.txt)
- [Other services from clinicalintelpulse.theaslangroupllc.com](https://www.zero.xyz/host/clinicalintelpulse.theaslangroupllc.com/llms.txt)